1. Synthesis, structure-activity relationship and antiviral activity of indole-containing inhibitors of Flavivirus NS2B-NS3 protease.
- Author
-
Nie S, Zhao J, Wu X, Yao Y, Wu F, Lin YL, Li X, Kneubehl AR, Vogt MB, Rico-Hesse R, and Song Y
- Subjects
- Antiviral Agents chemical synthesis, Antiviral Agents chemistry, Dose-Response Relationship, Drug, Indoles chemical synthesis, Indoles chemistry, Microbial Sensitivity Tests, Molecular Structure, RNA Helicases antagonists & inhibitors, RNA Helicases metabolism, Serine Endopeptidases metabolism, Structure-Activity Relationship, Viral Nonstructural Proteins metabolism, Antiviral Agents pharmacology, Indoles pharmacology, Viral Nonstructural Proteins antagonists & inhibitors, Zika Virus drug effects
- Abstract
Zika virus belongs to the Flavivirus family of RNA viruses, which include other important human pathogens such as dengue and West Nile virus. There are no approved antiviral drugs for these viruses. The highly conserved NS2B-NS3 protease of Flavivirus is essential for the replication of these viruses and it is therefore a drug target. Compound screen followed by medicinal chemistry optimization yielded a novel series of 2,6-disubstituted indole compounds that are potent inhibitors of Zika virus protease (ZVpro) with IC
50 values as low as 320 nM. The structure-activity relationships of these and related compounds are discussed. Enzyme kinetics studies show the inhibitor 66 most likely exhibited a non-competitive mode of inhibition. In addition, this series of ZVpro inhibitors also inhibit the NS2B-NS3 protease of dengue and West Nile virus with reduced potencies. The most potent compounds 66 and 67 strongly inhibited Zika virus replication in cells with EC68 values of 1-3 μM. These compounds are novel pharmacological leads for further drug development targeting Zika virus., Competing Interests: Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper., (Copyright © 2021 Elsevier Masson SAS. All rights reserved.)- Published
- 2021
- Full Text
- View/download PDF